March 8th 2024
During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, asked participants how they would approach therapy for a patient with metastatic non–small cell lung cancer when biomarker testing is not yet completed. This is the second of 2 articles based on this event.
February 14th 2024
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
TROPION-Lung01 Trial of Datopotamab Deruxtecan Meets PFS End Point in NSCLC
July 10th 2023Progression-free survival data from the phase 3 TROPION-Lung01 trial showed that datopotamab deruxtecan as treatment of metastatic non–small cell lung cancer crossed the threshold for statistical significance.
Read More
Pembrolizumab Maintains Efficacy After 5 Years in First-Line, PD-L1+, Advanced NSCLC
July 1st 2023Findings from the 5-year follow-up analysis of the phase 3 KEYNOTE-042 study continue to support frontline pembrolizumab as standard of care for PD-L1-positive, locally advanced/metastatic non–small cell lung cancer.
Read More
Rezivertinib Generates Promising CNS Efficacy in NSCLC With an EGFR T790M Mutation
June 19th 2023Individual data from 2 studies evaluating rezivertinib in patients with advanced non–small cell lung cancer harboring an EGFR T790M mutation and CNS metastases displayed encouraging efficacy and safety findings.
Read More
Real-World Data Shows Significant Increase of Biomarker Testing in Past Decade for NSCLC
May 8th 2023Looking at real-world data, researchers identified a large increase of biomarker testing for patients with early-stage non–small cell lung cancer, which indicates a continuing trend toward personalized treatment.
Read More
Langer Assesses Several Targeted Treatment Options in the Non–Small Cell Lung Cancer Landscape
April 19th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Corey J. Langer, MD, discussed the EMPOWER Lung-3 and POSEIDON trials of immunotherapy options in patients with non–small cell lung cancer.
Read More
Updated Results Show Promise for IBI351 Monotherapy in KRAS G12C-Mutated Advanced NSCLC
April 17th 2023Updated results from the phase 1 study of the bioavailable KRAS G12C inhibitor IBI351 showed that monotherapy was tolerable with promising activity in patients with advanced non–small cell lung cancer whose tumor harbored the KRAS G12C mutation.
Read More
Taletrectinib Sustains Positive Efficacy and Safety in ROS1-Positive NSCLC
April 7th 2023With 1.5 years of follow-up, the confirmed objective response rate was 92.5% among patients who were ROS1 tyrosine kinase inhibitor-naïve and 52.6% in crizotinib-pretreated patients in the phase 2 TRUST-I trial.
Read More
FDA Accepts sNDAs for Encorafenib and Binimetinib for BRAF V600-Mutated NSCLC
April 4th 2023Results from the phase 2 PHAROS trial of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic non–small cell lung cancer has led the FDA to accept supplemental new drug applications for the agents. Further data will be presented at an upcoming medical meeting.
Read More
Amivantamab Shows Long-term Efficacy/Safety in Post-Platinum EGFR Exon 20 Insertion+ NSCLC
April 2nd 2023Amivantamab treatment continued to show tolerability and efficacy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy.
Read More
Clinicians Must Address Unusual AEs of BRAF/MEK Inhibition for BRAF-Mutated NSCLC
March 17th 2023A case report published in The Journal of the National Comprehensive Cancer Center highlights the importance of being mindful of unusual adverse events associated with BRAF/MEK inhibition for patients with BRAF-mutated non–small cell lung cancer.
Read More
Different Types of Biomarker Testing Methods Used in Patients with NSCLC
January 31st 2023Drs Socinski and Sabari explain the different types of testing methods commonly used in their clinical practice and share advice for community oncologists who are testing for biomarkers in their patients with NSCLC.
Watch
The Importance of Molecular Testing Before Adjuvant Therapy for NSCLC
January 24th 2023During a Targeted Oncology case-based roundtable event, Edward S. Kim, MD, MBA, discussed adjuvant therapy options and the use of molecular testing in patients with earlier-stage non–small cell lung cancer. This is the first of 2 articles based on this event.
Read More